3-O-多德-l-甲酸的抗过敏活性
Takeru Koga1, Naoaki Kawahara2, Mei Aburada3
1Graduate School of Technology, Industrial and Social Sciences, Tokushima University, 2-1 Minamijosanjima-Cho, Tokushima 770-8513, Japan.
研究人员合成了 Askorbic 酸衍生物以抑制脱粒化. 3-O-dodecyl-l-ascorbic acid (化合物8) 在体外和体内表现出强大的抗过敏活性,这表明它有可能用于治疗过敏.
科学领域:
- 药用化学 医学化学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 亚酸 (维生素C) 衍生物正在研究治疗应用.
- 乳腺细胞降粒是过敏反应中的一个关键过程.
- 抑制脱粒化是抗过敏药物开发的目标策略.
研究的目的:
- 为了合成新的2-O-基和3-O-基酸衍生物.
- 为了评估这些衍生物的抑制作用对巨细胞脱粒的作用.
- 评估最有效化合物的体内抗过敏潜力.
主要方法:
- 合成各种基化甲酸衍生物.
- 在体外评估抗原和离子孔刺激的降粒的抑制活性.
- 在口服后对小鼠的被动皮肤过敏反应 (PCA) 的体内评估.
主要成果:
- 3-O-dodecyl-l-ascorbic acid (化合物8) 在测试的衍生物中表现出对抗原刺激脱粒的最强抑制.
- 化合物8也有效地抑制了离子孔诱导的脱粒.
- 口服的化合物8在小鼠PCA模型中显示出抗过敏功效,与oxatomide可比.
结论:
- 3-O-dodecyl-l-ascorbic 酸是一种强大的抑制剂,可以抑制巨细胞的脱粒化.
- 化合物8在体内表现出显著的抗过敏活性.
- 这种 Askorbic 酸衍生物代表了未来抗过敏疗法的有希望的候选者.
更多相关视频
08:25An Ex vivo Mast Cell Degranulation Assay using Crude Peritoneal Exudate Cells and Natural Antigen Stimulation
Published on: April 27, 2021
17:35A Microplate Assay to Assess Chemical Effects on RBL-2H3 Mast Cell Degranulation: Effects of Triclosan without Use of an Organic Solvent
Published on: November 1, 2013
相关概念视频
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Cholinergic Antagonists: Pharmacokinetics
Allergic Drug Reactions
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Adrenergic Agonists: Mixed-Action Agents
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
